In fact, this group showed intermediate tumour-growth control, that is, its efficacy was between that obtained after treatment with PBS only, as a negative control, and the groups treated with OT-I CD8+ T cells or with APS-MNP-loaded OT-I CD8+ T cells. The gene discussed is CD8A; the disease is neoplasm.